Wockhardt LimitedNSE: WOCKPHARMA

Press Release Sep 19 2024

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Wockhardt Limited submitted a press release regarding its investigational drug, Zaynich™ (Zidebactam/Cefepime), which successfully treated a complex case of meningitis caused by a pan-drug resistant super-bug under compassionate use. The release highlights a specific case where a patient with severe complications improved significantly after treatment with Zaynich™, demonstrating the drug's effectiveness against difficult infections. This case marks the first successful treatment of nosocomial meningitis caused by multidrug-resistant Pseudomonas with Zaynich™, showcasing its potential as a therapeutic option.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated September 19, 2024, titled "Wockhardt's Investigational Drug, Zaynich (Zidebactam/Cefepime) cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use".

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases